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Chk1 both arrests replication forks and enhances repair of DNA damage by phosphorylation of downstream
effectors. Metnase (also termed SETMAR) is a SET histone methylase and transposase nuclease protein that
promotes both DNA double strand break (DSB) repair and re-start of stalled replication forks. We previously found
that Chk1 phosphorylation of Metnase on S495 enhanced its DNA DSB repair activity but decreased its ability to
re-start stalled replication forks. Here we show that phosphorylated Metnase feeds back to increase the half-life
of Chk1. Chk1 half-life is regulated by DDB1 targeting it to Cul4A for ubiquitination and destruction. Metnase
decreases Chk1 interaction with DDB1, and decreases Chk1 ubiquitination. These data define a novel pathway for
Chk1 regulation, whereby a target of Chk1, Metnase, feeds back to amplify Chk1 stability, and therefore enhance
replication fork arrest.
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Metnase (also SETMAR) is a fusion of a SET [Su(var)3-9,
Enhancer-of-zeste, Trithorax] domain and a transposase
domain present only in anthropoid primates, and not
in other mammals [1]. The Metnase SET domain di-
methylates histone 3 lysine 36 (H3K36) [1], while the
transposase domain has most but not all of the classic
transposase nuclease activities, including 5’-terminal
inverted repeats (TIR)-specific DNA binding, DNA
looping, assembly of paired end complex (PEC), and
DNA cleavage [1,2].
We found that Metnase enhances non-homologous
end joining of DNA double strand breaks (DSB), perhaps
via its association with DNA Ligase IV [1,3]. Both the
histone methylase and nuclease domains are essential
for Metnase-mediated DNA DSB repair [1]. The SET
domain is responsible for di-methylating H3K36 adja-
cent to DNA DSBs, and this di-methylation stabilized
the Ku and MRN complexes at the DSB [4]. The trans-
posase nuclease domain can trim non-compatible free
DNA ends at a DSB, and thereby improve their end-joining* Correspondence: robert.hromas@medicine.ufl.edu
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article, unless otherwise stated.[5]. Metnase is also essential for proper re-starting of
stalled replication forks, perhaps by nicking and deca-
tenating positively supercoiled DNA in front of the
fork, resulting in decreased topological tension, enhan-
cing initial fork progression after re-start [6]. The
unique DDN catalytic motif in the nuclease domain of
Metnase is required for replication fork restart [7]. The
SET histone methyltransferase domain of Metnase is
also essential for fork repair and restart, but its specific
role has not been defined [6].
The repair of replication forks after arrest upon DNA
damage is regulated by a cascade of phosphorylation
events mediated by Chk1. We discovered that Metnase
is phosphorylated at S495 in response to DNA damage
by Chk1 [8]. Phosphorylation of Metnase increased its
DNA DSB repair capacity, but decreased its replication
fork restart activity. Thus, Metnase is a downstream
phosphorylation target of Chk1 that mediates the two
major activities of Chk1, enhancing DNA repair and
arresting replication forks [1,6,8].
In the concise study described here we found that
Metnase, itself a target of Chk1, increases the half-life
of total and phosphorylated Chk1 protein significantly.
We show that one potential mechanism for this may be
that Metnase reduces DDB1 interaction with Chk1,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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represents a novel pathway of Chk1 auto-regulation,
whereby one of its own targets amplifies its signal.
Human 293T cells were engineered to express wild
type and S495A mutant Metnase, which lacks the Chk1
phosphorylation site, and therefore cannot be phos-
phorylated, as we previously described [6,8]. Metnase
is ubiquitously expressed, except in cells transformed
with T antigen, which is synthetically lethal with Met-
nase. Thus, 293T cells do not express Metnase, making
them a useful model cell system to study the effects of
Metnase [6-8]. V5-tagged wild type (wt) and mutant
Metnase expression was confirmed by Western blot in
the engineered cells. The following antibodies were
used in the western and co-immunoprecipitation ex-
periments here: FLAG, actin (Sigma, St. Louis, MO);
Chk1, p317 Chk1, DDB1, ubiquitin (Cell Signaling,
Danvers, MA); and V5 (Invitrogen, Carlsbad, CA).
In our previous studies of the Chk1 phosphorylation
of Metnase on S495 [8], we noted that cells expressing
wt Metnase routinely appeared to have higher levels of
Chk1. WT Metnase represents a mixture of phosphor-
ylated and unphosphorylated Metnase species, while
S495A Metnase would represent only the unpho-
sphorylated species. The engineered 293T cell lines,
expressing either wt or S495A Metnase, were exposed
to cycloheximide (50 μg/mL) to arrest protein synthe-
sis, and total Chk1 and p296 Chk1 protein levels were
assessed using western analysis for protein stability,
as described [1,6,8]. WT Metnase markedly increased
the stability of total Chk1 protein in unstressed cells
(Figure 1A,B). However, S495A Metnase, which cannot
be phosphorylated by Chk1, did not appreciably alter
the half-life of Chk1 protein (Figure 1A,B). In this blot,
which was run longer to separate bands more efficiently,
there was also an increase in dual bands of the total Chk1
protein, which likely represented total and phosphorylated
Chk1 (Figure 1A). Therefore, whether wt Metnase in-
creased the stability of phosphorylated Chk1 was exam-
ined using western analysis of cycloheximide treated
cells as above. We found that wt Metnase increases the
initial steady state levels of phosphorylated Chk1 (p296)
at time 0, but does not alter the half-life of p296 Chk1
after cycloheximide exposure (Figure 1C,D). this gel was
run for a shorter time period., thus has a single Chk1
band. The auto-phosphorylation of Chk1 at 296 is a
final step in the activation of Chk1 kinase activity [8,9].
We next assessed whether Metnase repression from
siRNA in 293 cells, which do express Metnase, because
they are not transformed with T antigen, would also
decrease Chk1 protein levels (Figure 1E,F) after repli-
cation stress. WT Metnase repression using siRNA
resulted in a decrease in the steady state levels of total
and p317 Chk1, and a decrease in total Chk1 afterreplication stress with hydroxyurea (HU, 5 mM for
4 h). ATR phosphorylates Chk1 317 after HU, which is
important for initiating its auto-kinase activity, and
ultimately downstream of replication fork arrest [8,9].
Thus, the presence of wt Metnase, which itself is phos-
phorylated by Chk1, is important for the stability of
total Chk1 protein, both with and without replication
stress, although the affect is greater with replication
stress.
Chk1 protein stability is regulated by DDB1 targeting
Chk1 to the Cul4a E3 ligase for ubquitination and
destruction, and this ubiquitination is increased with
replication stress [9]. In the experiments described
above, wt Metnase, which is phosphorylated by Chk1,
was found to increase the half-life of Chk1 protein.
Therefore, we examined the interaction between DDB1
and Chk1 in the presence or absence of wt Metnase,
with or without exposure to HU (10 mM for 18 h). In
Figure 1E, we found that when wt Metnase was present
there was less interaction of Chk1 with DDB1, espe-
cially in the presence of HU. Significantly, when wt
Metnase was present, there was also a marked decrease
in the ubquitination of Chk1, especially during replica-
tion stress (Figure 1G). This which would result in
enhanced stability of Chk1 protein, and an increased
substrate for activation by ATR [9]. These data imply
that wt Metnase regulates Chk1 protein levels by de-
creasing its targeting by DDB1 to Cul4a for ubiquitina-
tion and proteasome destruction.
In summary, we found that Metnase stabilized Chk1
protein half-life, with or without replication stress. Upon
replication stress Chk1 is phosphorylated by ATR on
S317, which allows Chk1 to auto-phosphorylate, and ini-
tiate its downstream kinase cascade in the replication
stress response that results in replication arrest. DDB1
down-regulates Chk1 protein levels by targeting it to the
E3 ligase Cul4a for ubiquitination and destruction, even
during replication stress [9]. However, the mechanism
by which this destruction is regulated has not been clear.
What prevents DDB1 targeting of Chk1 for destruction
before the collapsed forks are repaired? This report
addresses a significant unanswered question in Chk1
regulation: How are Chk1 levels maintained during
replication stress? Here we demonstrate one possible
answer to this question: Metnase, itself a Chk1 phos-
phorylation target, decreases Chk1 interaction with
DDB1, and decreases subsequent Chk1 ubiquitination
during replication stress (Figure 1H). Metnase serves as a
switch for DDB1/Chk1 interaction, to enhance Chk1
protein stability during replication stress (Figure 1H).
We previously found that the unphosphorylated
Metnase species is far better at restarting replication
forks than the phosphorylated species, implying that Chk1
activity inhibited Metnase’s fork restart capability [8].
Figure 1 Metnase, itself a target of Chk1 phosphorylation, stabilizes Chk1 half-life. A, B- Western analysis showing Metnase stabilizes
Chk1 after cycloheximide, and this is largely dependent on Chk1 phosphorylation of S495, as the S495A Metnase species, which cannot be
phosphorylated, does not extend Chk1 protein half-life nearly as much. Total Chk1 levels were normalized to Chk1 present at time 0, before
cycloheximide exposure. C,D- Western analysis of p296 Chk1 half-life in cells with or without Metnase (pCAPP). The presence of wt Metnase
enhances the stability of phosphorylated Chk1. Phosphorylated Chk1 levels were normalized to time 0, before cycloheximide. E,F- Metnase
promotes Chk1, and ATR-mediated p317 Chk1 induction after exposure to the replication stressor hydroxyurea (HU). The quantitation in
panel F is the ratio of Chk1 or pChk1 in siRNA-Metnase cells divided by WT Metnase-expressing cells. This implies that the increase in
phosphorylated Chk1 is mainly due to the increase in total Chk1 protein stability, consistent with D. G- Metnase reduces Chk1 interaction
with DDB1, and reduces Chk1 ubiquitination. 293 T-pCAPP (which do not express Metnase due to T antigen) and 293 T-MET were transiently
transfected with FLAG-Chk1, and treated with HU, and then FLAG was immunoprecipitated. This immunoprecipitate was probed for DDB1
and ubiquitin. Metnase over-expression reduces association of Chk1 with DDB1. HU induces Chk1 ubiquitination, but this is largely blocked
by wt Metnase over-expression. A longer exposure of the ubiquitin autoradiogram is also presented. H- ATR phosphorylates Chk1 S317 upon
replication stress. Phosphorylated Chk1 phosphorylates S495 of Metnase. Phosphorylated Metnase decreases the interaction of DDB1 with
Chk1, reducing Chk1 targeting to the Cul4a E3 ubiquitin ligase, increasing Chk1 stability.
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suggest a layer of complexity in Chk1 signaling not
currently appreciated. Chk1 phosphorylates Metnase,
which decreases Metnase’s fork restart capability. Phos-
phorylated Metnase feeds back to stabilize Chk1 protein
half-life, and therefore increases the steady state levels
of phosphorylated Chk1. Phosphorylated Metnase is
inefficient in the restart of collapsed replication forks,
but it is recruited to DNA DSBs at higher rates, and
enhances DSB repair. With Chk1-mediated Metnase
phosphorylation there is further prolongation of the
Chk-1 half-life, resulting in additional Metnase phos-
phorylation, and further reduction in replication fork
restart, but further enhancement of DNA DSB repair.
Chk1 mediates cell cycle arrest after replication stress,
such as occurs during chemotherapy or low oxygen con-
ditions. This allows these cells to repair replication fork
damage before they enter mitosis, which would be cata-
strophic if unrepaired forks persisted. Thus, Chk1 has
become an important target for anti-neoplastic drug
development [10]. There are several Chk1 inhibitors in
clinical trials to treat cancer, and their common mech-
anism of action appears to be prevention of proper cell
cycle arrest to allow repair of stalled or collapsed forks
during replication stress, resulting in catastrophic mi-
tosis [10]. Triple negative breast cancer is an especially
appealing malignancy for treatment with Chk1 inhibi-
tors, since these cancers have faulty replication fork
repair, either from inherited or acquired BRCA1/2 defi-
ciencies. It is possible that high Metnase levels could
promote resistance to these Chk1 inhibitors by enhan-
cing Chk1 signaling. Thus, an inhibitor of Metnase,
such as one of the quinolone structures we described
previously [11], could be synthetically lethal with a
Chk1 inhibitor. Or, since Metnase mediates clonogenic
survival to HU [6], targeting Metnase could directly
cancer cell resistance to replication stressor drugs, such
as camptothecin or fluorouracil. Thus, this study pro-
vides a novel target for synthetic lethality in cancers
susceptible to Chk1 inhibition or replication stress.Competing interests
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